Home LiteratureArticle Details
PMID: 17957189 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Models, mechanisms and clinical evidence for cancer dormancy.

Nature reviews. Cancer ·Vol. 7 ·No. 11 ·2007-11-00 ·Pages 834-46

Aguirre-Ghiso JA

Abstract

Patients with cancer can develop recurrent metastatic disease with latency periods that range from years even to decades. This pause can be explained by cancer dormancy, a stage in cancer progression in which residual disease is present but remains asymptomatic. Cancer dormancy is poorly understood, resulting in major shortcomings in our understanding of the full complexity of the disease. Here, I review experimental and clinical evidence that supports the existence of various mechanisms of cancer dormancy including angiogenic dormancy, cellular dormancy (G0-G1 arrest) and immunosurveillance. The advances in this field provide an emerging picture of how cancer dormancy can ensue and how it could be therapeutically targeted.

MeSH Terms
Animals Disease Progression Drug Resistance, Neoplasm Epigenesis, Genetic Humans Mice Mice, Inbred Strains Mice, Transgenic Models, Biological Neoplasm Invasiveness/physiopathology Neoplasm Metastasis/physiopathology Neoplasm Proteins/physiology Neoplasm Recurrence, Local/physiopathology Neoplasm, Residual Neoplasms/blood supply,genetics,immunology,pathology Neovascularization, Pathologic/physiopathology Time Factors Tumor Burden Tumor Escape
Chemicals
Neoplasm Proteins
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Aguirre-Ghiso Julio A
Department of Biomedical Sciences, School of Public Health and Center for Excellence in Cancer Genomics, University at Albany, State University of New York, One Discovery Drive, Rensselaer, New York 12144-3456, USA. [email protected]
References (140)
140 references, click to expand
  1. Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells.
    Biochem Biophys Res Commun. 2000 Apr 2;270(1):108-11 PMID: 10733912
  2. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application.
    Clin Cancer Res. 2006 Jul 1;12(13):3882-9 PMID: 16818682
  3. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state.
    J Immunol. 1999 Mar 1;162(5):2842-9 PMID: 10072532
  4. Delayed ageing through damage protection by the Arf/p53 pathway.
    Nature. 2007 Jul 19;448(7151):375-9 PMID: 17637672
  5. Targeting HIF-1 for cancer therapy.
    Nat Rev Cancer. 2003 Oct;3(10):721-32 PMID: 13130303
  6. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction.
    Cancer Cell. 2004 Aug;6(2):159-70 PMID: 15324699
  7. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.
    J Mol Diagn. 2007 Apr;9(2):237-41 PMID: 17384216
  8. Minimal residual disease in gastrointestinal cancer.
    Semin Surg Oncol. 2001 Jun;20(4):282-93 PMID: 11747270
  9. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.
    Cancer Res. 2006 Feb 15;66(4):2264-70 PMID: 16489030
  10. The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination.
    J Exp Med. 1979 Mar 1;149(3):745-57 PMID: 429962
  11. Cell-cycle-specific induction of quiescence achieved by limited inhibition of protein synthesis: counteractive effect of addition of purified growth factors.
    J Cell Sci. 1985 Feb;73:375-87 PMID: 3894388
  12. Cancer. Addiction to oncogenes--the Achilles heal of cancer.
    Science. 2002 Jul 5;297(5578):63-4 PMID: 12098689
  13. A new description of cellular quiescence.
    PLoS Biol. 2006 Mar;4(3):e83 PMID: 16509772
  14. Cancer as an evolutionary and ecological process.
    Nat Rev Cancer. 2006 Dec;6(12):924-35 PMID: 17109012
  15. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness.
    Br J Dermatol. 2001 Aug;145(2):195-202 PMID: 11531779
  16. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.
    Blood. 2004 Oct 1;104(7):2124-33 PMID: 15191948
  17. The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice.
    J Exp Med. 1979 Mar 1;149(3):732-44 PMID: 311815
  18. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1.
    Nat Genet. 2005 Oct;37(10):1055-62 PMID: 16142231
  19. Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.
    J Chemother. 2003 Oct;15(5):495-502 PMID: 14598943
  20. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
    Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17361-5 PMID: 17079488
  21. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
    Cancer Res. 1997 Apr 1;57(7):1394-9 PMID: 9102229
  22. Disseminated tumor cells: diagnosis, prognostic relevance, and phenotyping.
    Recent Results Cancer Res. 2001;158:14-24 PMID: 11092029
  23. Metastasis: a question of life or death.
    Nat Rev Cancer. 2006 Jun;6(6):449-58 PMID: 16723991
  24. Caenorhabditis elegans OSR-1 regulates behavioral and physiological responses to hyperosmotic environments.
    Genetics. 2004 May;167(1):161-70 PMID: 15166144
  25. Tumour stem cells and drug resistance.
    Nat Rev Cancer. 2005 Apr;5(4):275-84 PMID: 15803154
  26. Minimal residual disease in non-small-cell lung cancer.
    Semin Surg Oncol. 2001 Jun;20(4):278-81 PMID: 11747269
  27. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.
    Cancer Cell. 2002 Dec;2(6):451-61 PMID: 12498714
  28. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value.
    J Urol. 2001 Aug;166(2):699-703 PMID: 11458120
  29. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer.
    Breast Cancer Res. 2006;8(2):R16 PMID: 16563182
  30. Metastasis suppressors alter the signal transduction of cancer cells.
    Nat Rev Cancer. 2003 Jan;3(1):55-63 PMID: 12509767
  31. Cancer stem cells and metastasis: lethal seeds.
    Clin Cancer Res. 2006 Oct 1;12(19):5606-7 PMID: 17020960
  32. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.
    Cell Cycle. 2006 Aug;5(16):1779-87 PMID: 16931911
  33. Detection and significance of minimal residual disease in colorectal cancer.
    Histol Histopathol. 1999 Apr;14(2):561-9 PMID: 10212818
  34. Role of angiogenesis in tumor growth and metastasis.
    Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 PMID: 12516034
  35. Global analysis of dauer gene expression in Caenorhabditis elegans.
    Development. 2003 Apr;130(8):1621-34 PMID: 12620986
  36. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span.
    Dev Cell. 2005 Nov;9(5):605-15 PMID: 16256736
  37. Circulating tumor cells in patients with breast cancer dormancy.
    Clin Cancer Res. 2004 Dec 15;10(24):8152-62 PMID: 15623589
  38. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer.
    Nat Med. 1995 Oct;1(10):1035-9 PMID: 7489359
  39. Tumor cell senescence in cancer treatment.
    Cancer Res. 2003 Jun 1;63(11):2705-15 PMID: 12782571
  40. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients.
    Semin Cancer Biol. 2001 Aug;11(4):307-11 PMID: 11513566
  41. Evidence for the clonal origin of spontaneous metastases.
    Science. 1982 Jul 23;217(4557):361-3 PMID: 6953592
  42. Detection and characterization of circulating and disseminated prostate cancer cells.
    Front Biosci. 2007 May 01;12:3000-9 PMID: 17485277
  43. Homozygous deletion of MKK4 in ovarian serous carcinoma.
    Cancer Biol Ther. 2006 Jun;5(6):630-4 PMID: 16627982
  44. EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells.
    Cancer Res. 1998 Dec 1;58(23):5439-46 PMID: 9850077
  45. Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis.
    J Cell Sci. 1999 Jun;112 ( Pt 12):1835-42 PMID: 10341203
  46. Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells.
    Proc Natl Acad Sci U S A. 1985 Aug;82(16):5365-9 PMID: 3860868
  47. Defining the epithelial stem cell niche in skin.
    Science. 2004 Jan 16;303(5656):359-63 PMID: 14671312
  48. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer.
    Cancer Cell. 2005 Sep;8(3):227-39 PMID: 16169467
  49. Human tumor antigens, immunosurveillance, and cancer vaccines.
    Immunol Res. 2006;36(1-3):73-82 PMID: 17337768
  50. Survival of leukemic cells in a dormant state following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (DL811).
    Int J Cancer. 1991 Sep 9;49(2):303-9 PMID: 1879974
  51. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis.
    Nat Med. 2000 Jan;6(1):100-2 PMID: 10613833
  52. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
    J Urol. 2003 Mar;169(3):1122-33 PMID: 12576866
  53. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.
    Cancer Cell. 2003 Mar;3(3):219-31 PMID: 12676581
  54. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases.
    Breast Cancer Res Treat. 2003 Dec;82(3):199-206 PMID: 14703067
  55. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention.
    Nature. 2006 May 25;441(7092):518-22 PMID: 16633340
  56. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Nat Rev Cancer. 2005 Apr;5(4):263-74 PMID: 15776005
  57. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression.
    Nat Med. 2006 Aug;12(8):933-8 PMID: 16862154
  58. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.
    Cancer Res. 2005 Dec 1;65(23):10984-91 PMID: 16322247
  59. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.
    Mol Biol Cell. 2001 Apr;12(4):863-79 PMID: 11294892
  60. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells.
    Immunology. 2005 Jul;115(3):325-36 PMID: 15946250
  61. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain.
    Magn Reson Med. 2006 Nov;56(5):1001-10 PMID: 17029229
  62. C. elegans DAF-18/PTEN mediates nutrient-dependent arrest of cell cycle and growth in the germline.
    Curr Biol. 2006 Apr 18;16(8):773-9 PMID: 16631584
  63. Tumour dormancy: findings and hypotheses from clinical research on breast cancer.
    Semin Cancer Biol. 2001 Aug;11(4):297-306 PMID: 11513565
  64. Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1.
    Cancer Cell. 2003 Mar;3(3):199-200 PMID: 12676576
  65. Host genetics influence tumour metastasis.
    Nat Rev Cancer. 2006 Feb;6(2):141-6 PMID: 16491073
  66. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics.
    Cell Cycle. 2006 Aug;5(16):1788-98 PMID: 16929175
  67. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype.
    J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 PMID: 16507828
  68. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.
    J Cell Biol. 1997 Apr 7;137(1):231-45 PMID: 9105051
  69. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth.
    Cancer Res. 2004 Oct 15;64(20):7336-45 PMID: 15492254
  70. Telomerase activity in disseminated prostate cancer cells.
    BJU Int. 2006 Jun;97(6):1309-13 PMID: 16686730
  71. Extracellular matrix signaling: integration of form and function in normal and malignant cells.
    Curr Opin Cell Biol. 1998 Oct;10(5):640-6 PMID: 9818175
  72. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis.
    Cancer Res. 2007 Apr 15;67(8):3734-40 PMID: 17440086
  73. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.
    Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4216-21 PMID: 16537511
  74. Dormant Wnt-initiated mammary cancer can participate in reconstituting functional mammary glands.
    Mol Cell Biol. 2007 Jan;27(1):195-207 PMID: 17060457
  75. Selection of early-occurring mutations dictates hormone-independent progression in mouse mammary tumor lines.
    J Virol. 2006 Nov;80(22):11409-15 PMID: 16971449
  76. Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.
    Leuk Lymphoma. 2001 Sep-Oct;42(5):933-44 PMID: 11697648
  77. Significance of minimal residual disease in lymphoid malignancies.
    Acta Haematol. 2004;112(1-2):111-9 PMID: 15179011
  78. Minimal residual disease in breast cancer.
    Cancer Metastasis Rev. 1999;18(1):101-8 PMID: 10505549
  79. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
    J Clin Oncol. 2002 Apr 15;20(8):2005-16 PMID: 11956259
  80. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.
    Nat Med. 1995 Feb;1(2):149-53 PMID: 7585012
  81. Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies.
    Mol Pharmacol. 2001 Nov;60(5):900-6 PMID: 11641417
  82. Minimal residual disease in melanoma.
    Semin Surg Oncol. 2001 Jun;20(4):319-28 PMID: 11747274
  83. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells?
    Cancer Biol Ther. 2006 Jul;5(7):729-35 PMID: 16861922
  84. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo.
    Oncogene. 2002 Apr 11;21(16):2513-24 PMID: 11971186
  85. Minimal residual disease in soft-tissue sarcomas.
    Semin Surg Oncol. 2001 Jun;20(4):294-303 PMID: 11747271
  86. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
    Nature. 2004 Oct 28;431(7012):1112-7 PMID: 15475948
  87. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
    Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71 PMID: 17056717
  88. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas.
    Nat Genet. 2005 Feb;37(2):182-6 PMID: 15640797
  89. Mutations that increase the life span of C. elegans inhibit tumor growth.
    Science. 2006 Aug 18;313(5789):971-5 PMID: 16917064
  90. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.
    Cancer Cell. 2002 Jun;1(5):445-57 PMID: 12124174
  91. A distinct "side population" of cells with high drug efflux capacity in human tumor cells.
    Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 PMID: 15381773
  92. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
    Clin Cancer Res. 2006 Oct 1;12(19):5615-21 PMID: 17020963
  93. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth.
    J Biol Chem. 2006 May 26;281(21):14852-63 PMID: 16547007
  94. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.
    Science. 1995 Nov 24;270(5240):1326-31 PMID: 7481820
  95. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.
    Cancer Res. 2002 Apr 1;62(7):2162-8 PMID: 11929839
  96. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients.
    Int J Cancer. 2001 Apr 1;92(1):96-105 PMID: 11279612
  97. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression.
    Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42 PMID: 12808139
  98. p38 MAP kinase's emerging role as a tumor suppressor.
    Adv Cancer Res. 2004;92:95-118 PMID: 15530558
  99. Cancer as a robust system: implications for anticancer therapy.
    Nat Rev Cancer. 2004 Mar;4(3):227-35 PMID: 14993904
  100. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).
    Cancer Res. 2003 Apr 1;63(7):1684-95 PMID: 12670923
  101. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells.
    Science. 2004 May 28;304(5675):1338-40 PMID: 15060285
  102. Solitary cancer cells as a possible source of tumour dormancy?
    Semin Cancer Biol. 2001 Aug;11(4):271-6 PMID: 11513562
  103. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.
    Cancer Cell. 2002 Sep;2(3):205-16 PMID: 12242153
  104. The power and the promise of oncogene-induced senescence markers.
    Nat Rev Cancer. 2006 Jun;6(6):472-6 PMID: 16723993
  105. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Urol Oncol. 2007 May-Jun;25(3):214-20 PMID: 17483018
  106. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis.
    Nat Cell Biol. 2007 May;9(5):493-505 PMID: 17450133
  107. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.
    N Engl J Med. 1997 Jan 30;336(5):317-23 PMID: 9011783
  108. Preparing the "soil": the premetastatic niche.
    Cancer Res. 2006 Dec 1;66(23):11089-93 PMID: 17145848
  109. Reversal of human cellular senescence: roles of the p53 and p16 pathways.
    EMBO J. 2003 Aug 15;22(16):4212-22 PMID: 12912919
  110. The p38 signal transduction pathway participates in the oxidative stress-mediated translocation of DAF-16 to Caenorhabditis elegans nuclei.
    Mech Ageing Dev. 2005 Jun-Jul;126(6-7):642-7 PMID: 15888317
  111. Metastasis suppressor genes: basic biology and potential clinical use.
    Clin Breast Cancer. 2003 Apr;4(1):51-62 PMID: 12744759
  112. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  113. TOR deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of mRNA translation.
    Curr Biol. 2002 Sep 3;12(17):1448-61 PMID: 12225660
  114. Tumor cell dormancy: an NCI workshop report.
    Cancer Biol Ther. 2007 Sep;6(9):1496-504 PMID: 17881897
  115. Dissemination and growth of cancer cells in metastatic sites.
    Nat Rev Cancer. 2002 Aug;2(8):563-72 PMID: 12154349
  116. Cell cycle quiescence of early lymphoid progenitors in adult bone marrow.
    Stem Cells. 2006 Dec;24(12):2703-13 PMID: 16931772
  117. Reversible tumorigenesis by MYC in hematopoietic lineages.
    Mol Cell. 1999 Aug;4(2):199-207 PMID: 10488335
  118. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
    J Clin Invest. 1994 Oct;94(4):1383-9 PMID: 7929813
  119. Significance, detection and markers of disseminated breast cancer cells.
    Endocr Relat Cancer. 2006 Dec;13(4):1033-67 PMID: 17158753
  120. Dissecting the metastatic cascade.
    Nat Rev Cancer. 2004 Jun;4(6):448-56 PMID: 15170447
  121. Tumorigenesis and the angiogenic switch.
    Nat Rev Cancer. 2003 Jun;3(6):401-10 PMID: 12778130
  122. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
    Nature. 2007 Feb 8;445(7128):656-60 PMID: 17251933
  123. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
    J Cell Biol. 1999 Oct 4;147(1):89-104 PMID: 10508858
  124. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5987-93 PMID: 17062670
  125. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
    Biochem J. 2001 Sep 15;358(Pt 3):673-9 PMID: 11535128
  126. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy.
    J Natl Cancer Inst. 2007 Feb 21;99(4):309-21 PMID: 17312308
  127. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells.
    Cancer Res. 2006 Feb 1;66(3):1702-11 PMID: 16452230
  128. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis.
    Cancer Res. 2001 Jul 15;61(14):5575-9 PMID: 11454710
  129. Seed dormancy and germination.
    Curr Opin Plant Biol. 2002 Feb;5(1):33-6 PMID: 11788305
  130. Minimal residual disease in head and neck cancer.
    Cancer Metastasis Rev. 1999;18(1):109-26 PMID: 10505550
  131. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.
    Blood. 2002 Jan 15;99(2):507-12 PMID: 11781231
  132. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.
    Science. 1999 Jul 9;285(5425):245-8 PMID: 10398599
  133. Cancer dormancy: from mice to man.
    Cell Cycle. 2006 Aug;5(16):1772-8 PMID: 16929181
  134. Dormancy of mammary carcinoma after mastectomy.
    J Natl Cancer Inst. 1999 Jan 6;91(1):80-5 PMID: 9890174
  135. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.
    Nature. 2005 Sep 1;437(7055):141-6 PMID: 16136144
  136. Anti-angiogenic therapies in cancer: achievements and open questions.
    Bull Cancer. 2007 Sep;94(9):753-62 PMID: 17878094
  137. Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.
    Adv Cancer Res. 2007;97:189-202 PMID: 17419946
  138. Progression of pregnancy-dependent mouse mammary tumors after long dormancy periods. Involvement of Wnt pathway activation.
    Cancer Res. 2004 Aug 1;64(15):5193-9 PMID: 15289324
  139. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer.
    Cancer Res. 2006 Aug 15;66(16):7849-53 PMID: 16912156
  140. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
    Int J Cancer. 2007 Apr 1;120(7):1465-71 PMID: 17205532
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2256
Email
[email protected]
Published
2007-11-00
Pages
834-46
Language
English
Region
England
NLM ID
101124168
PMCID
PMC2519109
Subset
IM
Grants
NCI NIH HHS · CA109182 · United States
NCI NIH HHS · R01 CA109182 · United States
NCI NIH HHS · R01 CA109182-04 · United States
NCI NIH HHS · R01 CA109182-03 · United States
NCI NIH HHS · R01 CA109182-02 · United States
NCI NIH HHS · R01 CA109182-01A1 · United States
External Links
PubMed source DOI: 10.1038/nrc2256 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2